Apellis (APLS) Q2 2025: Free Goods Hit $13M as Injection Growth Holds, New Kidney Launch Sets Up Second-Half Inflection
Apellis navigated persistent co-pay assistance headwinds with disciplined cost control and stable injection growth, while launching Empaveli into new rare kidney indications with an expanded label. The company’s capped royalty deal and broad label approvals set up a potential inflection in late 2025, though free goods usage and market access remain key watchpoints for margin and revenue visibility.
Summary
- Free Goods Pressure Persists: Elevated use of patient assistance and free drug programs continues to weigh on reported revenue.
- Kidney Launch Momentum: Empaveli’s new label expands addressable markets and underpins management’s blockbuster ambitions.
- Pipeline and Cost Discipline: Next-gen development and flat operating expenses support a path to sustainable profitability.
Performance Analysis
Apellis delivered total revenue of $178 million for Q2, with Sifovri, its C3 inhibitor for geographic atrophy (GA), accounting for $151 million. Sifovri injection demand grew 6% QoQ, but high levels of free goods—driven by ongoing co-pay assistance funding shortages—reduced reported revenue by approximately $13 million. Commercial doses totaled 82,000, with 13,000 free goods doses, reflecting the company’s continued reliance on patient support programs as market access challenges persist.
Empaveli, Apellis’s second C3-targeting drug, generated $21 million in revenue, up 5% sequentially, with compliance rates holding at 97%. The recent FDA label expansion for Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (ICMPGN) positions the asset for a rare nephrology launch in the back half of the year, with meaningful revenue expected to begin in Q4. Operating expenses fell to $212 million, reflecting disciplined cost management and providing a buffer as the company absorbs ongoing market headwinds.
- Revenue Impact from Free Goods: Approximately $13 million revenue headwind from high free goods utilization, with similar levels expected through year-end.
- Sifovri Market Share Leadership: Maintains over 60% total share and 55% of new patient starts in GA, despite competitive claims and market noise.
- Cash Position Strengthened: $370 million in cash plus a $275 million upfront from the capped royalty deal supports operations through profitability.
Management expects low to mid single-digit quarterly injection growth to continue, with the rare disease kidney launch and pipeline progress as key growth levers for the second half and beyond.
Executive Commentary
"This approval represents a breakthrough for patients as for the first time they can be treated with a C3 targeting therapy and one that achieves the trifecta of outcomes across all three key markers of these diseases, including proteinuria reduction, EGFR stabilization, and substantial clearance of C3 deposits."
Dr. Cedric Francois, Co-founder and Chief Executive Officer
"Utilization of Sifovri free goods remained high during the second quarter and impacted revenue by approximately $13 million. We expect a similar impact to quarterly revenue throughout the rest of 2025."
Tim Sullivan, Chief Financial Officer
Strategic Positioning
1. Sifovri’s Enduring Lead in GA
Sifovri, Apellis’s lead asset in geographic atrophy, continues to command the category by every major metric: revenue, new patient share, overall market share, and payer coverage. Management emphasized the product’s differentiated efficacy profile, robust long-term data, and flexible dosing (as few as six doses per year), which are resonating with retina specialists. Despite a competitor’s claims of rapid market share gains, Apellis pointed to more representative data sets and four-year extension study results as key differentiators for sustained leadership.
2. Empaveli’s Rare Kidney Expansion
The FDA approval of Empaveli for C3G and ICMPGN unlocks a new rare nephrology market of approximately 5,000 patients in the US, including pediatric and post-transplant populations. Apellis is executing a three-pillar launch strategy: raising disease awareness, establishing Empaveli as the treatment of choice among nephrologists, and securing broad access. Early demand signals are positive, with transitions underway from the Early Access Program and pent-up demand from patients awaiting approval. Management sees a clear path to blockbuster status as Empaveli becomes the preferred option in these indications.
3. Royalty Monetization and Capital Allocation
The capped royalty purchase agreement with Sobi provided $275 million upfront in exchange for 90% of future ex-US Empaveli royalties up to a defined cap, plus potential milestones. This deal validates the long-term growth potential of the rare kidney franchise, de-risks the balance sheet, and preserves upside beyond the cap. Combined with flat operating expenses and a strong cash position, Apellis is positioned to fund operations through to profitability.
4. Pipeline Advancement and Next-Gen Therapies
Apellis is progressing pivotal trials for Empaveli in delayed graft function (DGF) and focal segmental glomerulosclerosis (FSGS), both high-need kidney diseases with no approved therapies. Additionally, a Phase 2 trial has begun for a next-generation GA therapy combining Sifovri with siRNA APL-3007, aiming to boost efficacy and reduce injection burden. This pipeline diversification supports long-term growth beyond current indications.
5. Commercial Execution and Market Education
The company continues to invest in disease awareness, physician engagement, and direct-to-consumer campaigns to drive new patient starts and expand market penetration. Special focus is placed on educating both retina specialists and referring optometrists, as well as supporting patient access and reimbursement navigation through Apellis Assist programs. Effective communication and education remain central to unlocking further market opportunity.
Key Considerations
This quarter reflects Apellis’s ability to maintain operational discipline and segment leadership while absorbing external reimbursement and funding shocks. Execution on new launches and pipeline milestones will be critical for sustaining momentum into 2026.
Key Considerations:
- Co-Pay Assistance Volatility: Persistent funding gaps in third-party assistance programs continue to drive high free goods usage, impacting net revenues and margin visibility.
- Rare Nephrology Launch Execution: Early success in Empaveli’s expanded label will hinge on rapid physician adoption, payer coverage, and patient transitions from early access programs.
- Market Penetration Ceiling: Sifovri’s current penetration is just over 10% of the GA market, with leading adopters treating up to 30-50% of eligible patients—suggesting significant headroom but requiring ongoing education and access solutions.
- Pipeline Readouts and Next-Gen Differentiation: Timelines for pivotal kidney trials and next-generation GA therapies will shape long-term growth and competitive positioning.
- Competitive Data Integrity: Management’s emphasis on robust, long-term clinical data and broader data sets sets a high bar for competitors relying on shorter-term or less representative evidence.
Risks
Revenue remains exposed to third-party funding dynamics, with free goods expected to continue impacting reported sales through year-end. Competitive pressure in GA and rare nephrology could intensify as rivals pursue label expansions and new data. Market access, payer coverage, and patient adherence are ongoing operational risks, while pipeline execution and trial outcomes in new indications remain critical for future growth.
Forward Outlook
For Q3 2025, Apellis guided to:
- Low to mid single-digit injection growth for Sifovri, consistent with recent quarters
- Continued elevated free goods usage, with a similar revenue impact as Q2
For full-year 2025, management maintained guidance:
- Operating expenses in line with 2024
- Cash runway, including royalty proceeds, sufficient to reach sustainable profitability
Management highlighted several factors that will influence performance:
- Empaveli revenue inflection expected in Q4 as new kidney indications ramp
- Ongoing market education to drive incremental Sifovri penetration
Takeaways
Apellis’s Q2 results reinforce its leadership in GA and rare disease, though the company’s financials remain susceptible to external funding volatility. The Empaveli kidney launch and disciplined cost structure provide potential upside, while robust clinical data and pipeline progress underpin long-term value.
- Free Goods Drag: Persistent co-pay funding shortages drive elevated free drug use, clouding near-term revenue clarity even as injection demand grows steadily.
- Rare Kidney Launch as Catalyst: Empaveli’s expanded label and early launch momentum set up a potential revenue inflection in late 2025, with execution and access as key variables.
- Pipeline and Profitability Path: Next-gen development and flat OPEX support a credible path to profitability, but pipeline execution and market access will determine the pace and magnitude of future growth.
Conclusion
Apellis delivered stable operational growth and reinforced its category leadership despite persistent reimbursement headwinds. The upcoming Empaveli kidney launch and disciplined capital allocation create a foundation for future inflection, but market access and funding dynamics remain material uncertainties for investors to monitor.
Industry Read-Through
Apellis’s experience highlights the growing importance of patient access programs and the volatility they introduce to specialty pharma revenue streams. As co-pay assistance becomes a larger lever in rare disease and high-cost therapies, other biopharma players should anticipate similar revenue recognition and margin headwinds when third-party funding is unstable. The company’s focus on robust, long-term clinical data, physician education, and multi-pronged launch strategies offers a blueprint for sustaining leadership in competitive specialty markets. Royalty monetization deals, like Apellis’s Sobi agreement, may become more common as companies seek to balance near-term liquidity with long-term participation in asset upside.